Verona pharma completes enrollment in phase 3 enhance-1 trial evaluating ensifentrine for maintenance treatment of copd

Top-line data expected from enhance-2 in q3 2022 and enhance-1 around the end of 2022 top-line data expected from enhance-2 in q3 2022 and enhance-1 around the end of 2022

VRNA Ratings Summary

VRNA Quant Ranking